Skip to main content

Table 1 Demographic data, clinical features, and outcomes of patients with Acinetobacter ursingii and Acinetobacter baumannii bacteremia

From: A retrospective study of the incidence, clinical characteristics, identification, and antimicrobial susceptibility of bacteremic isolates of Acinetobacter ursingii

  Acinetobacter ursingii (n = 16) Acinetobacter baumannii (n = 252) p value
  n (%)/median (Q1-Q3)/mean ± S.D.  
Gender, male 7 (43.8 %) 183 (72.6 %) 0.01
Age in years (median, IQR) 66.6 (50.0–83.2) 68.7 (52.6–84.9) 0.61
Source
Respiratory tract 4 (25 %) 130 (51.6 %) 0.04
Intra-abdominal 1 (6.25 %) 18 (7.1 %) 0.89
Urinary tract 0 19 (7.5 %) 0.25
Intravenous device 0 12 (4.8 %) 0.37
Wound 0 10 (4.0 %) 0.42
Other 1 (6.25 %) 13 (5.2 %) 0.85
Unknown 10 (62.5 %) 50 (19.8 %) <0.01
Comorbidity
Diabetes mellitus 2 (12.5 %) 66 (26.2 %) 0.22
Hypertension 7 (43.8 %) 78 (31.0 %) 0.29
Coronary artery disease 2 (12.5 %) 30 (11.9 %) 0.94
Congestive heart failure 3 (18.8 %) 21 (8.3 %) 0.16
Chronic obstructive pulmonary disease 2 (12.5 %) 40 (15.9 %) 0.72
Cerebral vascular disease 2 (12.5 %) 47 (18.7 %) 0.54
Chronic kidney disease 3 (18.8 %) 47 (18.7 %) 0.99
End stage renal disease 1 (6.3 %) 11 (4.4 %) 0.72
Alcoholism 1 (6.3 %) 22 (8.7 %) 0.73
Malignancy 12 (75 %) 88 (34.9 %) <0.01
Solid malignancy 7 (43.8 %) 69 (27.4 %) 0.16
Hematologic malignancy 5 (31.3 %) 19 (7.5 %) <0.01
Neutropenia 4 (25.0 %) 9 (3.6 %) <0.01
Trauma 0 8 (3.2 %) 0.47
Surgery in 1 month 4 (25 %) 88 (34.92 %) 0.42
Procedure
Ventilator 4 (25 %) 137 (54.4 %) 0.02
Endotracheal tube or tracheostomy 4 (25 %) 187 (74.2 %) <0.01
Central venous catheter 6 (37.5 %) 130(51.6 %) 0.27
Artery line 6 (37.5 %) 52 (20.6 % 0.26
Foley catheter 6 (37.5 %) 157 (62.3 %) 0.05
Nasogastric tube 6 (37.5 %) 180 (71.4 %) <0.01
Thoracic drain 0 9 (3.6 %) 0.44
Hemodialysis 1 (6.25 %) 16 (6.35 %) 0.99
Total parental nutrition 1 (6.25 %) 24 (9.5 %) 0.66
Other
Chemotherapy 9 (56.3 %) 28 (11.1 %) <0.01
Steroid use 3 (18.8 %) 69 (27.4 %) 0.45
Shock 2 (12.5 %) 54 (21.4 %) 0.39
Acquired in ICU 3 (18.8 %) 160 (63.5 %) <0.01
APACHE II score (median, IQR) 17.1 (10.0–24.7) 24.9 (14.6–35.1) <0.01
Appropriate antimicrobial therapy 10 (62.5 %) 128 (50.8 %) 0.36
Hospitalized days (median, IQR) 28 (13–60) 39 (18–73.5) 0.56
Mortality
14-day mortality 1 (6.25 %) 75 (29.8 %) 0.04
28-day mortality 1 (6.25 %) 94 (37.3 %) 0.02
  1. The data were presented in number and percentage, unless indicated otherwise. IQR interquartile range, ICU intensive care unit, APACHE II Acute Physiology and Chronic Health Evaluation II